Anthera Pharmaceuticals Inc. (Nasdaq: ANTH) announced reported positive results from a Phase 2b PEARL-SC trial of its systemic lupus erythematosus treatment blisibimod. The stock price climbed 27 cents to close at $1.60.
Anthera Reports Positive Results
July 17, 2012 at 17:34 PM EDT